[go: up one dir, main page]

AR132377A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
AR132377A1
AR132377A1 ARP240100893A ARP240100893A AR132377A1 AR 132377 A1 AR132377 A1 AR 132377A1 AR P240100893 A ARP240100893 A AR P240100893A AR P240100893 A ARP240100893 A AR P240100893A AR 132377 A1 AR132377 A1 AR 132377A1
Authority
AR
Argentina
Prior art keywords
novel compounds
compounds
novel
methods
general formula
Prior art date
Application number
ARP240100893A
Other languages
English (en)
Inventor
Lewis Scott Aitken
Lea Aurelie Bouche
Wolfang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Christian Schnider
Jonathan Martin Shannon
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR132377A1 publication Critical patent/AR132377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general (1) en donde R¹, R², R³, A y W son como se describen en la presente, una composición que incluye los compuestos y métodos para usar los compuestos.
ARP240100893A 2023-04-12 2024-04-10 Compuestos novedosos AR132377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP23167556 2023-04-12

Publications (1)

Publication Number Publication Date
AR132377A1 true AR132377A1 (es) 2025-06-18

Family

ID=86006564

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240100893A AR132377A1 (es) 2023-04-12 2024-04-10 Compuestos novedosos

Country Status (4)

Country Link
CN (1) CN120897918A (es)
AR (1) AR132377A1 (es)
TW (1) TW202506689A (es)
WO (1) WO2024213552A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
CN119431251A (zh) * 2024-10-24 2025-02-14 上海凌凯科技股份有限公司 一种4-溴-3,6-二氯哒嗪的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230123471A (ko) * 2020-11-20 2023-08-23 데날리 테라퓨틱스 인크. 화합물, 조성물 및 방법
WO2022232632A1 (en) * 2021-04-30 2022-11-03 Denali Therapeutics Inc. Compounds, compositions, and methods

Also Published As

Publication number Publication date
CN120897918A (zh) 2025-11-04
WO2024213552A1 (en) 2024-10-17
TW202506689A (zh) 2025-02-16

Similar Documents

Publication Publication Date Title
AR131282A1 (es) Compuestos novedosos
AR131006A1 (es) Compuestos novedosos
CL2023003312A1 (es) Inhibidores de nlrp3
AR130984A1 (es) Compuestos novedosos
CL2022001091A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco (divisional de solicitud 202001871).
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
AR123424A1 (es) Nuevos compuestos heterocíclicos
AR131278A1 (es) Compuestos novedosos
AR132377A1 (es) Compuestos novedosos
CO2023014721A2 (es) Compuestos heterocíclicos
CL2024004085A1 (es) Compuestos macrocíclicos inhibidores de kras, uso para tratar cáncer.
CO2023016212A2 (es) Derivados de triazina y su uso en el tratamiento del cáncer
CL2022000802A1 (es) Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3
AR132456A1 (es) Compuestos novedosos
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida
CO2022002336A2 (es) Compuestos heterocíclicos
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CL2025000126A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CO2025003256A2 (es) Derivados novedosos deuterados de pirimidin-2-il sulfonamida
CL2025000125A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR133375A1 (es) Compuestos novedosos
AR133076A1 (es) Compuestos novedosos
AR131633A1 (es) Derivados novedosos de pirimidinil sulfonamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure